Healthy volunteers compare two methods of delivering navenibart
NCT ID NCT07635095
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial in 180 healthy adults compares two ways of giving the drug navenibart: by autoinjector or by vial and syringe. The goal is to see if both methods lead to similar drug levels in the blood and have similar safety. Participants receive one dose and are monitored in the clinic and during follow-up visits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- navenibart
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Fortrea Clinical Trials
RECRUITINGDaytona Beach, Florida, 32117, United States
-
Fortrea Clinical Trials
RECRUITINGDallas, Texas, 75247, United States
-
Fortrea Clinical Trials
RECRUITINGMadison, Wisconsin, 53704, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ACC017 be safely dosed? a trial seeks answers
- Can a fingerprint scan replace traditional drug tests?
- Gut feeling: could probiotics soothe the mind?
- A window to the brain? eye signals may track dopamine
- Can a common heartburn pill change how a cancer drug works?
- Breathing exercises may rewire tongue control — a pilot study puts the idea to the test